AURA

At a glance

Aura Biosciences, Inc. (AURA) is listed on NASDAQ and classified in Biotechnology, part of the Healthcare sector. It is headquartered in Boston, United States and has 113 employees. The company is worth $669.93M. Revenue was $0 in fiscal 2025. It reported a net loss of $106.19M. The share price is 32.2% below its 52-week high of $9.54. 5 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $4.38M. In that quarter, 1 of them reduced the position. No open-market insider trades in it were filed over the last 30 days.

Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.

Key metrics

Market cap

$669.93M

P/E

—

Forward P/E

—

P/B

2.1x

Dividend yield

0.00%

Payout

—

EPS

-$1.76

ROE

-53.48%

Profit margin

0.00%

Revenue growth

—

Beta

0.41

52-week high

$9.54

52-week low

$4.73

History

Year by year, from the annual reports; dividends from the payments themselves.

Investors holding this

Major managers that reported this stock in their latest 13F.

• IE
  Israel Englander− Reduced

  Millennium Management · Q2 2026
  $4.38M

  617.47K shares · 0.0% of portfolio
• RT
  Renaissance TechnologiesHeld

  Renaissance Technologies · Q2 2026
  $1.24M

  174.2K shares · 0.0% of portfolio
• CA
  Cliff AsnessHeld

  AQR Capital Management · Q2 2026
  $780.21K

  109.89K shares · 0.0% of portfolio

Indicators, year by year

The last 4 closed years, each at that year’s closing price and reported numbers.

Median of the years shown; P/E years above 200x are left out.

Others in the same sector

Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.

About the company